Cross-sectional study shows plasma pTau217 detects amyloid-β in individuals with neuronal synuclein disease, implying its potential as a reliable biomarker.
Key Points
Plasma pTau217 accurately detects amyloid-β in neuronal synuclein disease individuals.
In the discovery cohort, pTau217 demonstrated the highest diagnostic performance with an Area Under the Curve of 0.92.
Cross-sectional cohort analysis included 253 participants from multiple clinical settings and established robust cut points.
These findings suggest that plasma pTau217 could reduce the need for additional amyloid-β testing in 41-56% of clinically-defined LBD participants.